Pfizer, India's Biocon Scrap Insulin Pact

March 13, 2012
Pfizer was to sell cheaper copies of diabetes products in some emerging markets and in Europe that Biocon would make.

India's largest biotechnology firm, Biocon, and pharmaceutical giant Pfizer said on March 13 they would scrap a plan to sell insulin products, sending Biocon's shares plunging. Biocon shares fell as much as 11.09% to a low of 238 rupees on the Bombay Stock Exchange following the news. The shares then retraced to 254 rupees, still down five percent.

The companies said the split was due to "individual priorities" for their respective businesses, adding it was "in their best interest to move forward independently." They did not elaborate.

"The development will have a psychological impact for Biocon. It cannot find a joint venture partner like Pfizer every day," said Jagannadham Thunuguntla, head of research at SMC Global Securities.

According to the deal struck in October 2010, Pfizer was to sell cheaper copies of diabetes products in some emerging markets and in Europe that the Bangalore-headquartered Biocon would make.

The decision to abandon the tie-up comes at a time when multinational drug makers are increasingly tying up with Indian pharmas to source cheaper generic products for sale globally.

"Biocon will work with existing partners in several countries and pursue a commercial strategy on its own and through new alliances in other markets," its chairman Kiran Mazumdar Shaw said.

Pfizer's general manager Diem Nguyen said the firm would "continue in active research and business development for diabetes, which represents a huge unmet need."

Copyright Agence France-Presse, 2012

Popular Sponsored Recommendations

The Ultimate Ecommerce Excellence Checklist

Oct. 2, 2023
Scaling ecommerce operations is no easy task when your business is moving fast. Assess your current ecommerce maturity level and set optimization priorities with this practical...

Shifting Your Business from Products to Service-Based Business Models: Generating Predictable Revenues

Oct. 27, 2023
Executive summary on a recent IndustryWeek-hosted webinar sponsored by SAP

Digitally Transforming Data and Processes With Product Lifecycle Management

Oct. 29, 2023
Manufacturers face increasing challenges in product development as they strive to consistently deliver improved results. Discover how industry leaders are improving time-to-market...

You Cannot Stay Competitive by Bolting New Technologies to a Legacy ERP

Oct. 20, 2023
Read this white paper to understand the benefits of shifting to a next-generation ERP system as part of a DOP.

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!